Navigation Links
FDA: Treatment With Angiotensin Receptor Blockers for High Blood Pressure Does Not Increase Risk of Cancer
Date:6/2/2011

artan)
  • Cozaar (losartan)
  • Diovan (valsartan)
  • Micardis (telmisartan)
  • Teveten (eprosartan)
  • Several combination drug products

  • Sustained elevated blood pressure (hypertension) increases the risk of death, heart attacks, stroke, heart failure and kidney failure. That is why it is important to keep blood pressure at normal levels. There are many treatments available to control elevated blood pressure and ARBs are an important group of such treatments.  

    The FDA has determined that any concern about a relationship between ARB use and development of cancer has been resolved by this analysis. People currently taking any antihypertensive medication should not stop taking it without talking to their health care professional first.

    Adverse events associated with ARB medications should be reported to the FDA MedWatch program at www.fda.gov/medwatch.

    For information:


    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

    Media Inquiries: Sandy Walsh, 301-796-4669, <
    '/>"/>

    SOURCE U.S. Food and Drug Administration
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Argos Therapeutics Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
    2. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
    3. Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumos HydroCoil® Embolic System for Treatment of Cerebral Aneurysms
    4. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
    5. Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment
    6. Elekta and ScandiDos Sign Distributor Agreement for Pre-Treatment Verification Tool for Radiation Therapy
    7. DFINE StabiliT® Vertebral Augmentation System Product Innovation Offers Physicians Improved Flexibility and Ease-of-Use for the Treatment of Spinal Fractures
    8. Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment
    9. Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis
    10. EndyMed Announces the Worlds First 3DEEP RF Skin Tightening and Fractional Skin Resurfacing Combined Treatment Platform
    11. FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/2/2015)... 2015  DURECT Corporation (Nasdaq: DRRX ... the successful completion of a Phase 1 clinical ... DUR-928 is an endogenous, small-molecule, new chemical entity ... diseases such as nonalcoholic fatty liver disease (NAFLD) ... injuries such as acute kidney injury (AKI).        ...
    (Date:3/2/2015)... 2, 2015  Intrexon Corporation (NYSE: ... announced its fourth quarter and full year results ... Recent Developments: , Acquired ActoGeniX, a European ... in cellular therapeutics and other innovative products.  Its ... food-grade microbes ( Lactococcus lactis ) to generate ...
    (Date:3/2/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial ... 31, 2014. Financial highlights for the fourth quarter include revenues ... or $0.04 per share. This compares to revenues of $12.5 ... per share, for the fourth quarter of 2013. Financial highlights ... and a net loss of $68.4 million, or $0.56 per ...
    Breaking Medicine Technology:DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
    (Date:3/2/2015)... CA (PRWEB) March 02, 2015 Gummy ... gum reshaping procedures. Gum reshaping can involve one or several ... to regenerate lost gum tissue for a more even gum ... dark gum line treatment that can permanently lighten discolored ... total smile approach, which involves a personalized treatment plan to ...
    (Date:3/2/2015)... Burns Engineering's Lab-to-Lab Calibration Service offers ... Platinum Resistance Thermometers (SSPRTs) and industrial Resistance Temperature ... . . . guaranteed. Their metrology ... 200706-0), ISO 9001 and 17025 Certified and provides ... to 500°C, both ITS-90 and Callendar-van Dusen calibrations ...
    (Date:3/2/2015)... 2015 Over the last five years ... vendors seeking to expand their geographic presence and achieve ... to reach $6.2 billion by 2019 at CAGR of ... the U.S. and Canada and a major part of ... regions such as Asia-Pacific including China and India, Latin ...
    (Date:3/2/2015)... This year, the National Multiple Sclerosis Society’s annual awareness ... people across the country to unite, raise awareness, ... their best lives. MS Awareness Week is a special week ... the Society’s vision of a world free of MS. ... the central nervous system, interrupts the flow of information within ...
    (Date:3/2/2015)... Atlantic Information Services, Inc. (AIS) is pleased ... Health Plans: 2015 , the all-new 12th edition of ... plan market, with enrollment data and contact information for ... Available as a printed book containing the full directory ... tables and charts, as well as an electronic version, ...
    Breaking Medicine News(10 mins):Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2
    ... users were informed of their odds for cardiovascular ... Letting patients know how cholesterol boosts their heart ... researchers report. , Researchers at McGill University in ... the study) with cholesterol problems who were instructed ...
    ... In the very first trial of its kind in ... find out if water softeners can help in the ... by clinicians at The University of Nottingham has received ... National Institute for Health Research (NIHR) Health Technology Assessment ...
    ... , McGill University researchers have uncovered the crucial role ... onset of breast cancer. The research, led by Dr. William ... Institute for Cancer Research in Scotland was published the ... Academy of Sciences (PNAS). The study,s first author is Dr. ...
    ... Net Income Increases 22% and Royalty Income Increases 29% ... ... Unilens Vision Inc. (OTC,Bulletin Board: UVICF) (TSX Venture Exchange: UVI), ... operating results for the first quarter of FY2008., Net sales, ...
    ... Switzerland, November 29 Biolytix AG,( http://www.biolytix.ch ... UK Ltd ( http://www.affymetrix.com ) and offers ... R&D community under conditions,compliant with a stringent ... the leading CRO,s for molecular biological analysis ...
    ... 29 BlueCross BlueShield of South,Carolina and ... have,streamlined access to international dental services through ... Healthcare Inc., Earlier this year, Companion ... members access to medical and surgical treatment,at ...
    Cached Medicine News:Health News:Knowing Heart Risk Keeps Patients on Cholesterol Drugs 2Health News:Eczema sufferers test out benefits of water softeners 2Health News:Eczema sufferers test out benefits of water softeners 3Health News:McGill researchers link enzyme to breast cancer malignancy 2Health News:Unilens Vision Reports Record First Quarter Earnings and Royalty Income 2Health News:Unilens Vision Reports Record First Quarter Earnings and Royalty Income 3Health News:Unilens Vision Reports Record First Quarter Earnings and Royalty Income 4Health News:Biolytix to Offer Industrial Gene Expression Analysis and Genotyping Services Using Affymetrix' GeneChip(R) Technology 2Health News:S.C. BlueCross, BlueChoice HealthPlan Expand Global Offerings to Include Dental Services 2
    West lacrimal cannula blunt tip with side port....
    West lachrymal cannula, blunt tip with inner side opening, gently curved shaft....
    McIntyre lacrimal cannula, dual 0.3 mm side ports, straight....
    Shahinian lacrimal cannula, bullet shaped tip, 0.3 mm side opening, straight....
    Medicine Products: